M&A, Buybacks and C-Suite Shifts: KeyCorp and FactSet Top Estimates as PacBio Slashes Outlook
I'm LongbridgeAI, I can summarize articles.Mid-2026 earnings highlight stark divergences as KeyCorp authorizes a USD 3 billion buyback on revenue beats and FactSet expands Google Cloud AI ties. Meanwhile, PacBio slashes its full-year outlook amid a CEO transition, while Zions secures multifamily assets to fuel growth.
Mid-2026 fundamental divergence is coming into sharp focus, with financial and data service firms executing multi-billion-dollar buybacks and strategic M&A, while pressure mounts in the life sciences sector.
KeyCorp (KEY.US) led the pack with a clear earnings beat, posting Q2 EPS of USD 0.44 against consensus estimates of USD 0.42. The regional bank's revenue rose 6.7% year-over-year to USD 1.96 billion, paving the way for a massive USD 3 billion stock buyback program. Capital allocation remains aggressive: by mid-August, KeyCorp announced the redemption of USD 525 million in Series D preferred stock and finalized its acquisition of UK-based Clearwater Corporate Finance LLP, marking its initial foray into the Western European advisory market.
Zions Bancorporation (ZION.US) is also deploying capital to consolidate market share. The USD 89 billion asset lender completed its purchase of Basis Investment Group’s Fannie Mae and Freddie Mac multifamily business lines on August 3. Management paired this inorganic growth with immediate shareholder returns, authorizing a USD 75 million Q3 buyback and hiking its quarterly dividend by 6.7% to USD 0.48 per share.
On the financial data front, FactSet Research Systems (FDS.US) delivered steady Q3 fiscal 2026 results, with GAAP revenue climbing 6.4% to USD 622.9 million and adjusted EPS up 6.1% to USD 4.53. Beyond maintaining its USD 1.16 per share dividend and reaffirming full-year guidance, FactSet is leaning heavily into AI infrastructure, cementing a June 30 strategic partnership with Google Cloud to integrate advanced machine learning models into its data ecosystem.
The outlook is far more turbulent for Pacific Biosciences (PACB.US). The sequencing technology provider widely missed Q2 estimates, reporting just USD 39 million in revenue against the expected USD 44.27 million, alongside an adjusted loss of USD 0.14 per share. Triggering an immediate leadership overhaul, Mark Van Oene has replaced six-year veteran Christian Henry as CEO. The new management team immediately slashed 2026 revenue guidance to a range of USD 155 million to USD 165 million, signaling a pivot toward a leaner corporate structure to stabilize operations.